BACKGROUND: The Centers for Disease Control and Prevention recently recommended the expansion of human immunodeficiency virus (HIV) antibody testing. However, antibody tests have longer "window periods" after HIV acquisition than do nucleic acid amplification tests (NAATs). METHODS: Public Health-Seattle & King County offered HIV antibody testing to men who have sex with men (MSM) using the OraQuick Advance Rapid HIV-1/2 Antibody Test (OraQuick; OraSure Technologies) on oral fluid or finger-stick blood specimens or using a first- or second-generation enzyme immunoassay. The enzyme immunoassay was also used to confirm reactive rapid test results and to screen specimens from OraQuick-negative MSM prior to pooling for HIV NAAT. Serum specimens obtained from subsets of HIV-infected persons were retrospectively evaluated by use of other HIV tests, including a fourth-generation antigen-antibody combination assay. RESULTS: From September 2003 through June 2008, a total of 328 (2.3%) of 14,005 specimens were HIV antibody positive, and 36 (0.3%) of 13,677 antibody-negative specimens were NAAT positive (indicating acute HIV infection). Among 6811 specimens obtained from MSM who were initially screened by rapid testing, OraQuick detected only 153 (91%) of 169 antibody-positive MSM and 80% of the 192 HIV-infected MSM detected by the HIV NAAT program. HIV was detected in serum samples obtained from 15 of 16 MSM with acute HIV infection that were retrospectively tested using the antigen-antibody combination assay. CONCLUSIONS: OraQuick may be less sensitive than enzyme immunoassays during early HIV infection. NAAT should be integrated into HIV testing programs that serve populations that undergo frequent testing and that have high rates of HIV acquisition, particularly if rapid HIV antibody testing is employed. Antigen-antibody combination assays may be a reasonably sensitive alternative to HIV NAAT.
BACKGROUND: The Centers for Disease Control and Prevention recently recommended the expansion of human immunodeficiency virus (HIV) antibody testing. However, antibody tests have longer "window periods" after HIV acquisition than do nucleic acid amplification tests (NAATs). METHODS: Public Health-Seattle & King County offered HIV antibody testing to men who have sex with men (MSM) using the OraQuick Advance Rapid HIV-1/2 Antibody Test (OraQuick; OraSure Technologies) on oral fluid or finger-stick blood specimens or using a first- or second-generation enzyme immunoassay. The enzyme immunoassay was also used to confirm reactive rapid test results and to screen specimens from OraQuick-negative MSM prior to pooling for HIV NAAT. Serum specimens obtained from subsets of HIV-infectedpersons were retrospectively evaluated by use of other HIV tests, including a fourth-generation antigen-antibody combination assay. RESULTS: From September 2003 through June 2008, a total of 328 (2.3%) of 14,005 specimens were HIV antibody positive, and 36 (0.3%) of 13,677 antibody-negative specimens were NAAT positive (indicating acute HIV infection). Among 6811 specimens obtained from MSM who were initially screened by rapid testing, OraQuick detected only 153 (91%) of 169 antibody-positive MSM and 80% of the 192 HIV-infected MSM detected by the HIV NAAT program. HIV was detected in serum samples obtained from 15 of 16 MSM with acute HIV infection that were retrospectively tested using the antigen-antibody combination assay. CONCLUSIONS:OraQuick may be less sensitive than enzyme immunoassays during early HIV infection. NAAT should be integrated into HIV testing programs that serve populations that undergo frequent testing and that have high rates of HIV acquisition, particularly if rapid HIV antibody testing is employed. Antigen-antibody combination assays may be a reasonably sensitive alternative to HIV NAAT.
Authors: Joanne Stekler; Janine Maenza; Claire E Stevens; Paul D Swenson; Robert W Coombs; Robert W Wood; Mary S Campbell; David C Nickle; Ann C Collier; Matthew R Golden Journal: Clin Infect Dis Date: 2006-12-20 Impact factor: 9.079
Authors: Bernard M Branson; H Hunter Handsfield; Margaret A Lampe; Robert S Janssen; Allan W Taylor; Sheryl B Lyss; Jill E Clark Journal: MMWR Recomm Rep Date: 2006-09-22
Authors: Pragna Patel; Jeffrey D Klausner; Oliver M Bacon; Sally Liska; Melanie Taylor; Anthony Gonzalez; Robert P Kohn; William Wong; Sydney Harvey; Peter R Kerndt; Scott D Holmberg Journal: J Acquir Immune Defic Syndr Date: 2006-05 Impact factor: 3.731
Authors: Frances H Priddy; Christopher D Pilcher; Renee H Moore; Pradnya Tambe; Mahin N Park; Susan A Fiscus; Mark B Feinberg; Carlos del Rio Journal: J Acquir Immune Defic Syndr Date: 2007-02-01 Impact factor: 3.731
Authors: Brian Louie; Ernest Wong; Jeffrey D Klausner; Sally Liska; Frederick Hecht; Terri Dowling; Martha Obeso; Susan S Phillips; Mark W Pandori Journal: J Clin Microbiol Date: 2008-01-30 Impact factor: 5.948
Authors: S M Owen; C Yang; T Spira; C Y Ou; C P Pau; B S Parekh; D Candal; D Kuehl; M S Kennedy; D Rudolph; W Luo; N Delatorre; S Masciotra; M L Kalish; F Cowart; T Barnett; R Lal; J S McDougal Journal: J Clin Microbiol Date: 2008-03-05 Impact factor: 5.948
Authors: Joshua D O'Neal; Matthew R Golden; Bernard M Branson; Joanne D Stekler Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731
Authors: Eric M Ramos; Socorro Harb; Joan Dragavon; Paul Swenson; Joanne D Stekler; Robert W Coombs Journal: J Clin Virol Date: 2013-08-26 Impact factor: 3.168
Authors: Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier Journal: AIDS Res Hum Retroviruses Date: 2018-06-13 Impact factor: 2.205
Authors: Kevin P Delaney; Jacqueline Rurangirwa; Shelley Facente; Teri Dowling; Mike Janson; Thomas Knoble; Annie Vu; Yunyin W Hu; Peter R Kerndt; Jan King; Susan Scheer Journal: J Acquir Immune Defic Syndr Date: 2016-01-01 Impact factor: 3.731